Aspirin Labeling Should Reflect Risk-Based CVD Prevention, Bayer Says
This article was originally published in The Tan Sheet
Executive Summary
Aspirin therapy labeling should be revised to include an indication for primary prevention of myocardial infarction, reflecting a risk-based approach to cardiovascular disease prevention, Bayer maintains in a recent submission to FDA
You may also be interested in...
Aspirin Professional Labeling Change Not Backed By Science – Bayer
Aspirin professional labeling should not be modified to recommend a lower dosing range for secondary cardiovascular prevention, Bayer's Consumer Care Division says in recent comments to FDA
Aspirin Professional Labeling Change Not Backed By Science – Bayer
Aspirin professional labeling should not be modified to recommend a lower dosing range for secondary cardiovascular prevention, Bayer's Consumer Care Division says in recent comments to FDA
Aspirin Professional Labeling Change Not Backed By Science – Bayer
Aspirin professional labeling should not be modified to recommend a lower dosing range for secondary cardiovascular prevention, Bayer's Consumer Care Division says in recent comments to FDA